骨髓增生异常综合征(Myelodyspla-stic syndrome.MDS)是一组原因不明的造血干细胞多样性异常增生性疾病,骨髓出现不同程度的造血细胞质和量的改变。外周血细胞减少,临床常以不明原因的贫血或粒细胞和血小板数减少为其突出表现。骨髓造血细胞表现为一系两系或三个系列的细胞质与量的变化,故称之为骨髓增生异常综合征。目前对其分类、命名、发病机理、转归等仍有不少争议。1982年法、美、英一小组血液病工作者协作组(简称 F A B)对 MDS 的概念性行修改、充实,受到世界血液界广泛重视。随之诊断为 MDS 的病例日渐增多。本文就有关 Myelodysplasia syndrome (Myelodyspla-stic syndrome. MDS) is a group of unknown causes of hematopoietic stem cell-like dysplasia, bone marrow varying degrees of hematopoietic cytoplasm and volume changes. Peripheral blood cells, often clinically unexplained anemia or decreased number of granulocytes and platelets as its outstanding performance. Bone marrow hematopoietic cells showed a series of two or three series of cytoplasmic and quantitative changes, it is called myelodysplastic syndrome. At present, there is still a lot of controversy about its classification, naming, pathogenesis and outcome. 1982 France, the United States, Britain, a small group of Hematopathy Workers Collaboration (referred to as F A B) MDS conceptual line to modify, enrich, by the world blood sector wide attention. The subsequent diagnosis of MDS cases are increasing. This article is relevant